Anakinra dampens cytokine hyperinflammation in COVID-19

The biological DMARD anakinra (Kineret) may have a role in treating critically ill COVID-19 patients when there is a shortage of ventilators, according to Italian researchers. The interleukin (IL)-1 receptor antagonist was associated with improved survival and reduced markers of inflammation when used at high doses in patients with acute respiratory distress syndrome and hyperinflammation, ...

Already a member?

Login to keep reading.

© 2021 the limbic